Journal of the American Academy of Child & Adolescent Psychiatry
ARTICLESGrowth Deficits in ADHD Children Revisited: Evidence for Disorder-Associated Growth Delays?
REFERENCES (47)
Comparison of anthropometric measures of nutritional status in preschool children in five developing countries
Am J Clin Nutr
(1979)- et al.
Statistical methods and determination of sample size in the growth failure in children with renal diseases study
J Pediatr
(1990) - et al.
Impaired growth in hyperkinetic children receiving pemoline
Pediatrics
(1979) - et al.
Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate
J Am Acad Child Psychiatry
(1984) - et al.
Physical growth: National Center for Health Statistics percentiles
Am J Clin Nutr
(1979) - et al.
Young adult outcome of hyperactive children who received long-term stimulant treatment
J Am Acad Child Psychiatry
(1984) - et al.
Nocturnal Cortisol, thyroid stimulating hormone, and growth hormone secretory profiles in depressed adolescents
J Am Acad Child Adolesc Psychiatry
(1991) - et al.
Weight/length classification of nutritional status
Lancet
(1975) - et al.
Growth rebound after termination of stimulant drugs
J Pediatr
(1975) - et al.
Growth deficits in children treated with desipramine: a controlled study
J Am Acad Child Adolesc Psychiatry
(1992)
Clinical longitudinal standards for height and height velocity for North American children
J Pediatr
Note on the assessment and classification of protein-energy malnutrition in children
Lancet
Quantification of growth deficits in children with renal diseases
Semin Nephrol
A prospective four-year follow-up study of attention deficit hyperactivity and related disorders
Arch Gen Psychiatry
Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder (ADHD): patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples
Arch Gen Psychiatry
Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders
Am J Psychiatry
Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders
Arch Gen Psychiatry
Hyperactive children have grown up: what have we learned about what happens to them?
Arch Gen Psychiatry
Adolescents' self-assessment of sexual maturation
Pediatrics
Genetics of attention-deficit hyperactivity disorder
Child Adolesc Psychiatr Clin North Am
A family study of schizoaffective, bipolar I, bipolar II, unipolar and normal control probands
Arch Gen Psychiatry
Methylphenidate and growth in hyperactive children: a controlled withdrawal study
Arch Gen Psychiatry
Hyperactive boys almost grown up III: methylphenidate effects on ultimate height
Arch Gen Psychiatry
Cited by (190)
Editorial: Height and Stimulant Treatment in Attention-Deficit/Hyperactivity Disorder Youth: Mind the Gap
2023, Journal of the American Academy of Child and Adolescent PsychiatryAssociations Between Attention-Deficit/Hyperactivity Disorder (ADHD), ADHD Medication, and Shorter Height: A Quasi-Experimental and Family-Based Study
2023, Journal of the American Academy of Child and Adolescent PsychiatryReduced exercise-induced growth hormone secretion among children with attention-deficit hyperactivity disorder
2022, Growth Hormone and IGF ResearchLong term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Some data suggest that these effects attenuate over time so that final adult stature is not affected by prior stimulant exposure (Faraone et al., 2008; Biederman et al., 2010; Kramer et al., 2000; Peyre et al., 2013). Finally, other authors reported that the height or weight changes might be a natural symptom of ADHD rather than a consequence of medication (Spencer et al., 1996; Hanc and Cieslik, 2008; Swanson et al., 2007). While, on average, reported effects of stimulants on growth appear to be modest, a substantial variability has been observed, with some children seemingly completely unaffected (Biederman et al., 2010; Findling et al., 2009; Zachor et al., 2006), whilst others experience significant growth suppression (Pliszka et al., 2006b; Charach et al., 2006; Zhang et al., 2010; Poulton et al., 2012).
Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder
2020, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :The trajectory analysis expands and provides new information concerning the previously published endpoint analyses of adult height in the MTA14 by identifying periods in development (mean age 11.7 years and mean age 14.9 years) that might be most associated with a medication-related growth suppression. Most important, the Negligible subgroup’s z height trajectory showed a peak at the 3- and 6-year assessments (at 11.7 and 14.9 years of age) followed by a decline and stability by the 8-year assessment (at 16.8 years of age), suggesting faster-than-average tempo in the stimulant-untreated cases, the opposite of the Spencer et al.6,7 prediction that untreated children with ADHD would experience slower-than-average tempo, smaller size in childhood, and disorder-related catch-up in adolescence. This report has several strengths.
Preparation of this article was supported by NIMH grant K20 MH01169-01 (Dr. Spencer).